---
layout: page
image:
  feature: DaubEnginePatent.jpg
---
   <head>
      <title>2105-</title>
      <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
</head>
      <li><a href="index.html">Manual of Patent Examining Procedure</a></li>
      <li><a href="mpep-2100.html"><span>Chapter 2100</span></a></li>
      <li><span>Section 2105</span></li>  </ul>
      <div id="yui-main">
         <div class="yui-b">
            <div class="yui-g">  <div xmlns:bf="http://www.uspto.gov/bf" id="article">
               <div>
                  <div xmlns="" class="Section" id="d0e197008">
                     <h1 class="page-title">2105
                        &nbsp;&nbsp;
                        Patentable Subject Matter — Living Subject Matter [R-08.2012]
                     </h1>
                     <p id="d0e197016">The decision of the Supreme Court in <i>Diamond v. Chakrabarty,</i> 447 U.S. 303, 206 USPQ 193 (1980), held that
                        microorganisms produced by genetic engineering are not excluded from patent protection by
                        <b><a href="mpep-9015-appx-l.html#d0e302376">35&nbsp;U.S.C. 101</a></b>. It is clear from the Supreme Court decision and
                        opinion that the question of whether or not an invention embraces living matter is
                        irrelevant to the issue of patentability. The test set down by the Court for patentable
                        subject matter in this area is whether the living matter is the result of human
                        intervention. 
                     </p>
                     <p id="d0e197025">In view of this decision, the Office has issued these
                        guidelines as to how <b><a href="mpep-9015-appx-l.html#d0e302376">35 U.S.C. 101</a></b> will be
                        interpreted.
                     </p>
                     <p id="d0e197031">The Supreme Court made the following points in the <i>Chakrabarty </i>opinion: 
                     </p>
                     <blockquote id="d0e197037">
                        <p id="d0e197038">1. “Guided by these canons of construction, this Court has
                           read the term ‘manufacture’ in <b><a href="mpep-9015-appx-l.html#d0e302376">§ 101</a></b> in accordance with its
                           dictionary definition to mean ‘the production of articles for use from raw materials
                           prepared by giving to these materials new forms, qualities, properties, or combinations
                           whether by hand labor or by machinery.’”
                        </p>
                        <p id="d0e197043">2. “In choosing such expansive terms as ‘manufacture’ and
                           ‘composition of matter,’ modified by the comprehensive ‘any,’ Congress plainly
                           contemplated that the patent laws would be given wide scope.”
                        </p>
                        <p id="d0e197045">3. “The Act embodied Jefferson’s philosophy that ‘ingenuity
                           should receive a liberal encouragement.’ 5 Writings of Thomas Jefferson, at 75-76. See
                           <i>Graham </i>v<i>. John Deere
                              Co.,</i> 383 U.S. 1, 7-10, 148 USPQ459, 462-464 (1966). Subsequent patent
                           statutes in 1836, 1870, and 1874 employed this same broad language. In 1952, when the
                           patent laws were recodified, Congress replaced the word ‘art’ with ‘process,’ but
                           otherwise left Jefferson’s language intact. The Committee Reports accompanying the 1952
                           act inform us that Congress intended statutory subject matter to ‘include any thing
                           under the sun that is made by man.’ S. Rep. No. 1979, 82d Cong., 2d Sess., 5 (1952).” 
                        </p>
                        <p id="d0e197053">4. “This is not to suggest that <b><a href="mpep-9015-appx-l.html#d0e302376">§
                                 101</a></b> has no limits or that it embraces every discovery. The laws of
                           nature, physical phenomena, and abstract ideas have been held not patentable.” 
                        </p>
                        <p id="d0e197058">5. “Thus, a new mineral discovered in the earth or a new
                           plant found in the wild is not patentable subject matter. Likewise, Einstein could not
                           patent his celebrated law that E=mc<sup>2</sup>; nor
                           could Newton have patented the law of gravity.” 
                        </p>
                        <p id="d0e197063">6. “His claim is not to a hitherto unknown natural
                           phenomenon, but to a nonnaturally occurring manufacture or composition of matter
                           <sup>__ </sup>a product of human ingenuity ‘having a
                           distinctive name, character [and] use.’” 
                        </p>
                        <p id="d0e197068">7. “Congress thus recognized that the relevant distinction
                           was not between living and inanimate things, but between products of nature, whether
                           living or not, and human-made inventions. Here, respondent’s microorganism is the result
                           of human ingenuity and research.”
                        </p>
                        <p id="d0e197070">8. After reference to <i>Funk Seed
                              Co. &amp; Kalo Co.,</i> 333 U.S. 127, 76 USPQ 280 (1948), “Here, by contrast,
                           the patentee has produced a new bacterium with markedly different characteristics from
                           any found in nature and one having the potential for significant utility. His discovery
                           is not nature’s handiwork, but his own; accordingly it is patentable subject matter
                           under <b><a href="mpep-9015-appx-l.html#d0e302376">§
                                 101</a></b>.” 
                        </p>
                     </blockquote>
                     <p id="d0e197079">A review of the Court statements above as well as the whole
                        <i>Chakrabarty</i> opinion reveals:
                     </p>
                     <div id="d0e197085" class="List">
                        <ul style="list-style-type: none;">
                           <li id="d0e197086" class="nobull">(A) That the Court did not limit its decision to
                              genetically engineered living organisms;
                           </li>
                           <li id="d0e197090" class="nobull">(B) The Court enunciated a very broad interpretation of
                              “manufacture” and “composition of matter” in <b><a href="mpep-9015-appx-l.html#d0e302376">35 U.S.C. 101</a></b>
                              (Note esp. quotes 1, 2, and 3 above);
                           </li>
                           <li id="d0e197097" class="nobull">(C) The Court set forth several tests for weighing
                              whether patentable subject matter under <b><a href="mpep-9015-appx-l.html#d0e302376">35 U.S.C. 101</a></b>
                              is present, stating (in quote 7 above) that:
                           </li>
                        </ul>
                     </div>
                     <blockquote id="d0e197104">
                        <p id="d0e197105">The relevant distinction was not between living and
                           inanimate things but between products of nature, whether living or not, and human-made
                           inventions.
                        </p>
                     </blockquote>
                     <p id="d0e197108">The tests set forth by the Court are (note especially the
                        italicized portions):
                     </p>
                     <div id="d0e197111" class="List">
                        <ul style="list-style-type: none;">
                           <li id="d0e197112" class="nobull">(A) “The laws of nature, physical phenomena and abstract
                              ideas” are not patentable subject matter.
                           </li>
                           <li id="d0e197116" class="nobull">(B) A “nonnaturally occurring manufacture or composition
                              of matter — a product of human ingenuity —having a distinctive name, character,
                              [and] use” is patentable subject matter.
                           </li>
                           <li id="d0e197120" class="nobull">(C) “[A] new mineral discovered in the earth or a new
                              plant found in the wild is not patentable subject matter. Likewise, Einstein could
                              not patent his celebrated E=mc<sup>2</sup>; nor
                              could Newton have patented the law of gravity. Such discoveries are
                              ‘manifestations of... nature, free to all men and reserved exclusively to none.’”
                              
                           </li>
                           <li id="d0e197127" class="nobull">(D) “[T]he production of articles for use from raw
                              materials prepared by giving to these materials <i>new
                                 forms, qualities, properties, or combinations whether by hand labor or by
                                 machinery”</i> [emphasis added] is a “manufacture” under
                              <b><a href="mpep-9015-appx-l.html#d0e302376">35 U.S.C.
                                    101</a></b>.
                           </li>
                        </ul>
                     </div>
                     <p id="">Following the reasoning in <i>Chakrabarty,</i> the Board of Patent
                        Appeals and Interferences determined that animals are patentable subject matter under
                        <b><a href="mpep-9015-appx-l.html#d0e302376">35
                              U.S.C. 101</a></b>. In <i>Ex parte Allen,</i> 2 USPQ2d 1425 (Bd.
                        Pat. App. &amp; Inter. 1987), the Board decided that a polyploid Pacific coast oyster could
                        have been the proper subject of a patent under <b><a href="mpep-9015-appx-l.html#d0e302376">35 U.S.C. 101</a></b> if all the criteria for
                        patentability were satisfied. Shortly after the <i>Allen</i> decision, the
                        Commissioner of Patents and Trademarks issued a notice (Animals - Patentability, 1077 O.G.
                        24, April 21, 1987) that the Patent and Trademark Office would now consider nonnaturally
                        occurring, nonhuman multicellular living organisms, including animals, to be patentable
                        subject matter within the scope of <b><a href="mpep-9015-appx-l.html#d0e302376">35&nbsp;U.S.C. 101</a></b>.
                     </p>
                     <p id="ch2100_d1b145_1bb89_366">The Leahy-Smith America Invents Act (AIA), Pub.
                        L. 112-29, <b><a href="mpep-9015-appx-l.html#aiasec33limitonissuance">sec. 33(a)</a></b>, 125 Stat. 284, states:
                     </p>
                     <blockquote id="">
                        <p id="ch2100_d1b145_1bcfd_cf"> Notwithstanding any other provision of law,
                           no patent may issue on a claim directed to or encompassing a human
                           organism.
                        </p>
                     </blockquote>
                     <p id="">The legislative history of the AIA includes the following statement, which
                        sheds light on the meaning of this provision:
                     </p>
                     <blockquote id="">
                        <p id="">[T]he U.S. Patent Office has already issued patents on genes, stems cells,
                           animals with human genes, and a host of non-biologic products used by humans, but it has
                           not issued patents on claims directed to human organisms, including human embryos and
                           fetuses. My amendment would not affect the former, but would simply affirm the
                           latter.
                        </p>
                     </blockquote>
                     <p id="">157 Cong. Rec. E1177-04 (testimony of Representative Dave Weldon previously
                        presented in connection with the Consolidated Appropriations Act, 2004, Pub. L. 108-199, '
                        634, 118 Stat. 3, 101, and later resubmitted with regard to the AIA; see 149 Cong. Rec.
                        E2417-01). Thus, section 33(a) of the AIA codifies existing Office policy that human
                        organisms are not patent-eligible subject matter. 
                     </p>
                     <p id="d0e197229">If the broadest reasonable interpretation of the claimed
                        invention as a whole encompasses a humanorganism, then a rejection under <b><a href="mpep-9015-appx-l.html#d0e302376">35 U.S.C.
                              101</a></b> and <b><a href="mpep-9015-appx-l.html#aiasec33limitonissuance">AIA sec. 33(a)</a></b> must be made indicating
                        that the claimed invention is directed to a human organism and is therefore nonstatutory
                        subject matter. Form paragraph
                        <b><a href="#">7.04.01</a></b> may be used; see
                        <b><a href="s706.html#d0e66135">MPEP §
                              706.03(a)</a></b>. Furthermore, the claimed invention must be examined
                        with regard to all issues pertinent to patentability, and any applicable rejections under
                        <b><a href="mpep-9015-appx-l.html#d0e302383">35
                              U.S.C. 102</a></b>, <b><a href="mpep-9015-appx-l.html#d0e302450">103</a></b>, or <b><a href="mpep-9015-appx-l.html#d0e302824">112</a></b>
                        must also be made.
                     </p>
                     <p id="ch2100_d1b145_1d660_1cf">With respect to plant subject matter, the
                        Supreme Court held that patentable subject matter under <b><a href="mpep-9015-appx-l.html#d0e302376">35 U.S.C. 101</a></b> includes newly developed
                        plant breeds, even though plant protection is also available under the Plant Patent Act
                        (<b><a href="mpep-9015-appx-l.html#d0e304416">35 U.S.C.
                              161</a></b> - <b><a href="mpep-9015-appx-l.html#d0e304454">164</a></b>) and the Plant Variety Protection
                        Act (7 U.S.C. 2321 <i>et. seq.</i>). <i>J.E.M. Ag Supply, Inc. v. Pioneer
                           Hi-Bred Int’ l, Inc.,</i> 534 U.S. 124, 143-46, 122 S.Ct. 593, 605-06, 60 USPQ2d
                        1865, 1874 (2001) (The scope of coverage of <b><a href="mpep-9015-appx-l.html#d0e302376">35 U.S.C. 101</a></b> is not limited by the
                        Plant Patent Act or the Plant Variety Protection Act; each statute can be regarded as
                        effective because of its different requirements and protections). In analyzing the history
                        of the Plant Patent Act of 1930, the Court stated: “In enacting the Plant Patent Act,
                        Congress addressed both of these concerns [the concern that plants, even those artificially
                        bred, were products of nature for purposes of the patent law and the concern that plants
                        were thought not amenable to the written description]. It explained at length its belief
                        that the work of the plant breeder ‘in aid of nature’ was patentable invention. S. Rep. No.
                        315, 71st Cong., 2d Sess., 6-8 (1930); H.R. Rep. No. 1129, 71st Cong., 2d Sess., 7-9
                        (1930).” See also<i> Ex parte Hibberd,</i> 227 USPQ 443 (Bd. Pat. App. &amp;
                        Inter. 1985), wherein the Board held that plant subject matter may be the proper subject of
                        a patent under <b><a href="mpep-9015-appx-l.html#d0e302376">35 U.S.C.
                              101</a></b> even though such subject matter may be protected under the Plant
                        Patent Act or the Plant Variety Protection Act.
                     </p>
                     <p align="right"><a href="#top">[top]</a></p>
                  </div>
               </div>
               <div>
                  <h1 class="page-title">&nbsp;</h1>
               </div>  </div>
            </div>
         </div>
      </div>
      <div class="yui-b">
         <div id="aside">  <div id="rdms-sub-nav-container" xmlns:bf="http://www.uspto.gov/bf">
            <ul id="sub-nav">
               <li xmlns=""><a href="s2101-2102.html">2101-2102-[Reserved]</a></li>
               <li xmlns=""><a href="s2103.html">2103-Patent Examination Process</a></li>
               <li xmlns=""><a href="s2104.html">2104-Patentable Subject Matter</a></li>
               <li xmlns=""><a href="s2105.html">2105-Patentable Subject Matter — Living Subject Matter</a></li>
               <li xmlns=""><a href="s2106.html">2106-Patent Subject Matter Eligibility</a><ul>
                     <li><a href="s2106.html#d0e198001">2106.01-Subject Matter Eligibility Analysis of Process Claims Involving Laws of Nature</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2107.html">2107-Guidelines for Examination of Applications for Compliance with the Utility Requirement</a><ul>
                     <li><a href="s2107.html#d0e198682">2107.01-General Principles Governing Utility Rejections</a></li>
                     <li><a href="s2107.html#d0e199419">2107.02-Procedural Considerations Related to Rejections for Lack of Utility</a></li>
                     <li><a href="s2107.html#d0e200058">2107.03-Special Considerations for Asserted Therapeutic or Pharmacological Utilities</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2108-2110.html">2108-2110-[Reserved]</a></li>
               <li xmlns=""><a href="s2111.html">2111-Claim Interpretation; Broadest Reasonable Interpretation</a><ul>
                     <li><a href="s2111.html#d0e200409">2111.01-Plain Meaning</a></li>
                     <li><a href="s2111.html#d0e200689">2111.02-Effect of Preamble</a></li>
                     <li><a href="s2111.html#d0e200824">2111.03-Transitional Phrases</a></li>
                     <li><a href="s2111.html#d0e201000">2111.04-“Adapted to,” “Adapted for,” “Wherein,” and “Whereby” Clauses</a></li>
                     <li><a href="s2111.html#ch2100_d1b148_1ea0c_2c0">2111.05-Functional and Nonfunctional Descriptive Material</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2112.html">2112-Requirements of Rejection Based on Inherency; Burden of Proof</a><ul>
                     <li><a href="s2112.html#d0e201273">2112.01-Composition, Product, and&nbsp; Apparatus Claims</a></li>
                     <li><a href="s2112.html#d0e201360">2112.02-Process Claims</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2113.html">2113-Product-by-Process Claims</a></li>
               <li xmlns=""><a href="s2114.html">2114-Apparatus and Article Claims — Functional Language</a></li>
               <li xmlns=""><a href="s2115.html">2115-Material or Article Worked Upon by Apparatus</a></li>
               <li xmlns=""><a href="s2116.html">2116-Material Manipulated in Process</a><ul>
                     <li><a href="s2116.html#d0e201660">2116.01-Novel, Unobvious Starting Material or End Product</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2117-2120.html">2117-2120-[Reserved]</a></li>
               <li xmlns=""><a href="s2121.html">2121-Prior Art; General Level of Operability Required to Make a Prima Facie Case</a><ul>
                     <li><a href="s2121.html#d0e201800">2121.01-Use of Prior Art in Rejections Where Operability is in Question</a></li>
                     <li><a href="s2121.html#d0e201868">2121.02-Compounds and Compositions — What Constitutes Enabling Prior Art</a></li>
                     <li><a href="s2121.html#d0e201937">2121.03-Plant Genetics — What Constitutes Enabling Prior Art</a></li>
                     <li><a href="s2121.html#d0e201980">2121.04-Apparatus and Articles — What Constitutes Enabling Prior Art</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2122.html">2122-Discussion of Utility in the Prior Art</a></li>
               <li xmlns=""><a href="s2123.html">2123-Rejection Over Prior Art’s Broad Disclosure Instead of Preferred Embodiments</a></li>
               <li xmlns=""><a href="s2124.html">2124-Exception to the Rule That the Critical Reference Date Must Precede the Filing Date</a><ul>
                     <li><a href="s2124.html#ch2100_d1b13f_20224_b9">2124.01-Tax Strategies Deemed Within the Prior Art</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2125.html">2125-Drawings as Prior Art</a></li>
               <li xmlns=""><a href="s2126.html">2126-Availability of a Document as a “Patent” for Purposes of Rejection Under 35 U.S.C. 102(a) or Pre-AIA 35 U.S.C. 102(a), (b),
                     and (d)</a><ul>
                     <li><a href="s2126.html#d0e202293">2126.01-Date of Availability of a Patent as a Reference</a></li>
                     <li><a href="s2126.html#d0e202334">2126.02-Scope of Reference’s Disclosure Which Can Be Used to Reject Claims When the Reference Is a “Patent” but Not a “Publication”</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2127.html">2127-Domestic and Foreign Patent Applications as Prior Art</a></li>
               <li xmlns=""><a href="s2128.html">2128-“Printed Publications” as Prior Art</a><ul>
                     <li><a href="s2128.html#d0e202706">2128.01-Level of Public Accessibility Required</a></li>
                     <li><a href="s2128.html#d0e202804">2128.02-Date Publication Is Available as a Reference</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2129.html">2129-Admissions as Prior Art</a></li>
               <li xmlns=""><a href="s2130.html">2130-[Reserved]</a></li>
               <li xmlns=""><a href="s2131.html">2131-Anticipation — Application of 35&nbsp;U.S.C. 102</a><ul>
                     <li><a href="s2131.html#d0e203057">2131.01-Multiple Reference 35 U.S.C. 102 Rejections</a></li>
                     <li><a href="s2131.html#d0e203166">2131.02-Genus-Species Situations</a></li>
                     <li><a href="s2131.html#d0e203269">2131.03-Anticipation of Ranges</a></li>
                     <li><a href="s2131.html#d0e203338">2131.04-Secondary Considerations</a></li>
                     <li><a href="s2131.html#d0e203351">2131.05-Nonanalogous or Disparaging Prior Art</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2132.html">2132-Pre-AIA 35 U.S.C. 102(a)</a><ul>
                     <li><a href="s2132.html#d0e203530">2132.01-Publications as Pre-AIA 35 U.S.C. 102(a) Prior Art</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2133.html">2133-Pre-AIA 35 U.S.C. 102(b)</a><ul>
                     <li><a href="s2133.html#d0e203726">2133.01-Rejections of Continuation-In-Part (CIP) Applications</a></li>
                     <li><a href="s2133.html#d0e203739">2133.02-Rejections Based on Publications and Patents</a></li>
                     <li><a href="s2133.html#d0e203781">2133.03-Rejections Based on “Public Use” or “On Sale”</a><ul style="list-style-type: none">
                           <li><a href="s2133.html#d0e203899">2133.03(a)-“Public Use”</a></li>
                           <li><a href="s2133.html#d0e204201">2133.03(b)-“On Sale”</a></li>
                           <li><a href="s2133.html#d0e204494">2133.03(c)-The “Invention”</a></li>
                           <li><a href="s2133.html#d0e204651">2133.03(d)-“In This Country”</a></li>
                           <li><a href="s2133.html#d0e204670">2133.03(e)-Permitted Activity; Experimental Use</a><ul>
                                 <li><a href="s2133.html#d0e204712">2133.03(e)(1)-Commercial Exploitation</a></li>
                                 <li><a href="s2133.html#d0e204884">2133.03(e)(2)-Intent</a></li>
                                 <li><a href="s2133.html#d0e204900">2133.03(e)(3)-“Completeness” of the Invention</a></li>
                                 <li><a href="s2133.html#d0e204981">2133.03(e)(4)-Factors Indicative of an Experimental Purpose</a></li>
                                 <li><a href="s2133.html#d0e205019">2133.03(e)(5)-Experimentation and Degree of Supervision and Control</a></li>
                                 <li><a href="s2133.html#d0e205061">2133.03(e)(6)-Permitted Experimental Activity and Testing</a></li>
                                 <li><a href="s2133.html#d0e205133">2133.03(e)(7)-Activity of an Independent Third Party Inventor</a></li>
                              </ul>
                           </li>
                        </ul>
                     </li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2134.html">2134-Pre-AIA 35 U.S.C. 102(c)</a></li>
               <li xmlns=""><a href="s2135.html">2135-Pre-AIA 35 U.S.C. 102(d)</a><ul>
                     <li><a href="s2135.html#d0e205339">2135.01-The Four Requirements of Pre-AIA 35 U.S.C. 102(d)</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2136.html">2136-Pre-AIA 35 U.S.C. 102(e)</a><ul>
                     <li><a href="s2136.html#d0e205680">2136.01-Status of U.S. Application as a Reference</a></li>
                     <li><a href="s2136.html#d0e205829">2136.02-Content of the Prior Art Available Against the Claims</a></li>
                     <li><a href="s2136.html#d0e205924">2136.03-Critical Reference Date</a></li>
                     <li><a href="s2136.html#d0e206254">2136.04-Different Inventive Entity; Meaning of “By Another”</a></li>
                     <li><a href="s2136.html#d0e206333">2136.05-Overcoming a Rejection Under Pre-AIA 35&nbsp;U.S.C. 102(e)</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2137.html">2137-Pre-AIA 35 U.S.C. 102(f)</a><ul>
                     <li><a href="s2137.html#d0e206713">2137.01-Inventorship</a></li>
                     <li><a href="s2137.html#d0e206972">2137.02-Applicability of Pre-AIA 35 U.S.C. 103(c)</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2138.html">2138-Pre-AIA 35 U.S.C. 102(g)</a><ul>
                     <li><a href="s2138.html#d0e207148">2138.01-Interference Practice</a></li>
                     <li><a href="s2138.html#d0e207398">2138.02-“The Invention Was Made in This Country”</a></li>
                     <li><a href="s2138.html#d0e207478">2138.03-“By Another Who Has Not Abandoned, Suppressed, or Concealed It”</a></li>
                     <li><a href="s2138.html#d0e207607">2138.04-“Conception”</a></li>
                     <li><a href="s2138.html#d0e207753">2138.05-“Reduction to Practice”</a></li>
                     <li><a href="s2138.html#d0e207967">2138.06-“Reasonable Diligence”</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2139-2140.html">2139-2140-[Reserved]</a></li>
               <li xmlns=""><a href="s2141.html">2141-Examination Guidelines for Determining Obviousness Under 35 U.S.C. 103</a><ul>
                     <li><a href="s2141.html#d0e208803">2141.01-Scope and Content of the Prior Art</a><ul style="list-style-type: none">
                           <li><a href="s2141.html#d0e208985">2141.01(a)-Analogous and Nonanalogous Art</a></li>
                        </ul>
                     </li>
                     <li><a href="s2141.html#d0e209106">2141.02-Differences Between Prior Art and Claimed Invention</a></li>
                     <li><a href="s2141.html#d0e209300">2141.03-Level of Ordinary Skill in the Art</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2142.html">2142-Legal Concept of Prima Facie Obviousness</a></li>
               <li xmlns=""><a href="s2143.html">2143-Examples of Basic Requirements of a Prima Facie Case of Obviousness</a><ul>
                     <li><a href="s2143.html#d0e210245">2143.01-Suggestion or Motivation To Modify the References</a></li>
                     <li><a href="s2143.html#d0e210414">2143.02-Reasonable Expectation of Success Is Required</a></li>
                     <li><a href="s2143.html#d0e210501">2143.03-All Claim Limitations Must Be Considered</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2144.html">2144-Supporting a Rejection Under 35 U.S.C. 103</a><ul>
                     <li><a href="s2144.html#d0e210719">2144.01-Implicit Disclosure</a></li>
                     <li><a href="s2144.html#d0e210732">2144.02-Reliance on Scientific Theory</a></li>
                     <li><a href="s2144.html#d0e210752">2144.03-Reliance on Common Knowledge in the Art or “Well Known” Prior Art</a></li>
                     <li><a href="s2144.html#d0e210929">2144.04-Legal Precedent as Source of Supporting Rationale</a></li>
                     <li><a href="s2144.html#d0e211255">2144.05-Obviousness of Ranges</a></li>
                     <li><a href="s2144.html#d0e211480">2144.06-Art Recognized Equivalence for the Same Purpose</a></li>
                     <li><a href="s2144.html#d0e211558">2144.07-Art Recognized Suitability for an Intended Purpose</a></li>
                     <li><a href="s2144.html#d0e211596">2144.08-Obviousness of Species When Prior Art Teaches Genus</a></li>
                     <li><a href="s2144.html#d0e212153">2144.09-Close Structural Similarity Between Chemical Compounds (Homologs, Analogues, Isomers)</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2145.html">2145-Consideration of Applicant’s Rebuttal Arguments</a></li>
               <li xmlns=""><a href="s2146.html">2146-Pre-AIA 35 U.S.C. 103(c)</a></li>
               <li xmlns=""><a href="s2147-2149.html">2147-2149-[Reserved]</a></li>
               <li xmlns=""><a href="s2150.html">2150-Examination Guidelines for 35 U.S.C. 102 and 103 as Amended by the First Inventor To File Provisions of the Leahy-Smith America
                     Invents Act</a></li>
               <li xmlns=""><a href="s2151.html">2151-Overview of the Changes to 35 U.S.C. 102 and 103 in the AIA</a></li>
               <li xmlns=""><a href="s2152.html">2152-Detailed Discussion of AIA 35 U.S.C. 102(a) and (b)</a><ul>
                     <li><a href="s2152.html#ch2100_d20033_1afb3_e6">2152.01-Effective Filing Date of the Claimed Invention</a></li>
                     <li><a href="s2152.html#ch2100_d20033_1d66c_1e5">2152.02-Prior Art Under AIA 35 U.S.C. 102(a)(1) (Patented, Described in a Printed Publication, or in Public Use, on Sale, or Otherwise
                           Available to the Public)</a><ul style="list-style-type: none">
                           <li><a href="s2152.html#ch2100_d20033_1d6c2_3b7">2152.02(a)-Patented</a></li>
                           <li><a href="s2152.html#ch2100_d20033_1da60_2e9">2152.02(b)-Described in a Printed Publication</a></li>
                           <li><a href="s2152.html#ch2100_d20033_1e416_252">2152.02(c)-In Public Use</a></li>
                           <li><a href="s2152.html#ch2100_d20033_2254b_3e0">2152.02(d)-On Sale</a></li>
                           <li><a href="s2152.html#ch2100_d20033_228c0_21c">2152.02(e)-Otherwise Available to the Public</a></li>
                           <li><a href="s2152.html#ch2100_d20033_232ba_27c">2152.02(f)-No Requirement of "By Others"</a></li>
                        </ul>
                     </li>
                     <li><a href="s2152.html#ch2100_d20033_23444_146">2152.03-Admissions</a></li>
                     <li><a href="s2152.html#ch2100_d20033_236db_f9">2152.04-The Meaning of "Disclosure"</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2153.html">2153-Prior Art Exceptions Under 35 U.S.C. 102(b)(1) to AIA 35 U.S.C. 102(a)(1)</a><ul>
                     <li><a href="s2153.html#ch2100_d20033_24caf_cd">2153.01-Prior Art Exception Under AIA 35 U.S.C. 102(b)(1)(A) To AIA 35 U.S.C. 102(a)(1) (Grace Period Inventor Or Inventor-Originated
                           Disclosure Exception)</a><ul style="list-style-type: none">
                           <li><a href="s2153.html#ch2100_d20033_24e66_2ac">2153.01(a)-Grace Period Inventor Disclosure Exception</a></li>
                           <li><a href="s2153.html#ch2100_d20033_256f4_147">2153.01(b)-Grace Period Inventor-Originated Disclosure Exception</a></li>
                        </ul>
                     </li>
                     <li><a href="s2153.html#ch2100_d20033_25935_125">2153.02-Prior Art Exception Under AIA 35 U.S.C. 102(b)(1)(B) to AIA 35 U.S.C. 102(a)(1) (Inventor Or Inventor-Originated Prior Public
                           Disclosure Exception)</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2154.html">2154-Provisions Pertaining to Subject Matter in a U.S. Patent or Application Effectively Filed Before the Effective Filing Date
                     of the Claimed Invention</a><ul>
                     <li><a href="s2154.html#ch2100_d20033_27642_39b">2154.01-Prior Art Under AIA 35 U.S.C. 102(a)(2) “U.S. Patent Documents”</a><ul style="list-style-type: none">
                           <li><a href="s2154.html#ch2100_d20034_11f3b_a0">2154.01(a)-WIPO Published Applications</a></li>
                           <li><a href="s2154.html#ch2100_d20034_12188_300">2154.01(b)-Determining When Subject Matter Was Effectively Filed Under AIA 35 U.S.C. 102(d)</a></li>
                           <li><a href="s2154.html#ch2100_d20034_13884_7c">2154.01(c)-Requirement Of “Names Another Inventor”</a></li>
                        </ul>
                     </li>
                     <li><a href="s2154.html#ch2100_d20034_139ac_31b">2154.02-Prior Art Exceptions Under 35 U.S.C. 102(b)(2) to AIA 35 U.S.C. 102(a)(2)</a><ul style="list-style-type: none">
                           <li><a href="s2154.html#ch2100_d20034_13f89_241">2154.02(a)-Prior Art Exception Under AIA 35 U.S.C. 102(b)(2)(A) to AIA 35 U.S.C. 102(a)(2) (Inventor-Originated Disclosure Exception)</a></li>
                           <li><a href="s2154.html#ch2100_d20034_140df_1a6">2154.02(b)-Prior Art Exception Under AIA 35 U.S.C. 102(b)(2)(B) to AIA 35 U.S.C. 102(a)(2) (Inventor or Inventor-Originated Prior Public
                                 Disclosure Exception)</a></li>
                           <li><a href="s2154.html#ch2100_d20034_145f0_210">2154.02(c)-Prior Art Exception Under AIA 35 U.S.C. 102(b)(2)(C) to AIA 35 U.S.C. 102(a)(2) (Common Ownership or Obligation of Assignment)</a></li>
                        </ul>
                     </li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2155.html">2155-Use of Affidavits or Declarations Under 37 CFR 1.130 To Overcome Prior Art Rejections</a><ul>
                     <li><a href="s2155.html#ch2100_d20034_17271_83">2155.01-Showing That the Disclosure Was Made by the Inventor or a Joint Inventor</a></li>
                     <li><a href="s2155.html#ch2100_d20034_173e3_369">2155.02-Showing That the Subject Matter Disclosed Had Been Previously Publicly Disclosed by the Inventor or a Joint Inventor</a></li>
                     <li><a href="s2155.html#ch2100_d20034_1891a_11">2155.03-Showing That the Disclosure was Made, or That Subject Matter had Been Previously Publicly Disclosed, by Another Who Obtained
                           the Subject Matter Disclosed Directly or Indirectly From the Inventor or a Joint Inventor</a></li>
                     <li><a href="s2155.html#ch2100_d20034_19332_1dd">2155.04-Enablement</a></li>
                     <li><a href="s2155.html#ch2100_d20034_1b102_307">2155.05-Who May File an Affidavit or Declaration Under 37 CFR 1.130</a></li>
                     <li><a href="s2155.html#ch2100_d20034_1b27e_391">2155.06-Situations in Which an Affidavit or Declaration Is Not Available</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2156.html">2156-Joint Research Agreements</a></li>
               <li xmlns=""><a href="s2157.html">2157-Improper Naming of Inventors</a></li>
               <li xmlns=""><a href="s2158.html">2158-AIA 35 U.S.C. 103</a></li>
               <li xmlns=""><a href="s2159.html">2159-Applicability Date Provisions and Determining Whether an Application Is Subject to the First Inventor To File Provisions of
                     the AIA</a><ul>
                     <li><a href="s2159.html#ch2100_d20034_1dc9d_3c4">2159.01-Applications Filed Before March 16, 2013</a></li>
                     <li><a href="s2159.html#ch2100_d20034_1dfd4_279">2159.02-Applications Filed on or After March 16, 2013</a></li>
                     <li><a href="s2159.html#ch2100_d222e3_13adb_2f9">2159.03-Applications Subject to the AIA but Also Containing a Claimed Invention Having an Effective Filing Date Before March 16, 2013</a></li>
                     <li><a href="s2159.html#ch2100_d222e3_140d7_1bb">2159.04-Applicant Statement in Transition Applications Containing a Claimed Invention Having an Effective Filing Date on or After
                           March 16, 2013</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2160.html">2160-[Reserved]</a></li>
               <li xmlns=""><a href="s2161.html">2161-Three Separate Requirements for Specification Under 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph</a><ul>
                     <li><a href="s2161.html#d0e213447">2161.01-Computer Programming and 35 U.S.C. 112(a) or Pre-AIA 35&nbsp;U.S.C. 112, First Paragraph</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2162.html">2162-Policy Underlying 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph</a></li>
               <li xmlns=""><a href="s2163.html">2163-Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) or Pre-AIA 35&nbsp;U.S.C. 112, para. 1, “Written
                     Description” Requirement</a><ul>
                     <li><a href="s2163.html#d0e214533">2163.01-Support for the Claimed Subject Matter in Disclosure</a></li>
                     <li><a href="s2163.html#d0e214553">2163.02-Standard for Determining Compliance With the Written Description Requirement</a></li>
                     <li><a href="s2163.html#d0e214623">2163.03-Typical Circumstances Where Adequate Written Description Issue Arises</a></li>
                     <li><a href="s2163.html#d0e214731">2163.04-Burden on the Examiner with Regard to the Written Description Requirement</a></li>
                     <li><a href="s2163.html#d0e214820">2163.05-Changes to the Scope of Claims</a></li>
                     <li><a href="s2163.html#d0e215023">2163.06-Relationship of Written Description Requirement to New Matter</a></li>
                     <li><a href="s2163.html#d0e215099">2163.07-Amendments to Application Which Are Supported in the Original Description</a><ul style="list-style-type: none">
                           <li><a href="s2163.html#d0e215172">2163.07(a)-Inherent Function, Theory, or Advantage</a></li>
                           <li><a href="s2163.html#d0e215198">2163.07(b)-Incorporation by Reference</a></li>
                        </ul>
                     </li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2164.html">2164-The Enablement Requirement</a><ul>
                     <li><a href="s2164.html#d0e215268">2164.01-Test of Enablement</a><ul style="list-style-type: none">
                           <li><a href="s2164.html#d0e215360">2164.01(a)-Undue Experimentation Factors</a></li>
                           <li><a href="s2164.html#d0e215447">2164.01(b)-How to Make the Claimed Invention</a></li>
                           <li><a href="s2164.html#d0e215491">2164.01(c)-How to Use the Claimed Invention</a></li>
                        </ul>
                     </li>
                     <li><a href="s2164.html#d0e215531">2164.02-Working Example</a></li>
                     <li><a href="s2164.html#d0e215634">2164.03-Relationship of Predictability of the Art and the Enablement Requirement</a></li>
                     <li><a href="s2164.html#d0e215702">2164.04-Burden on the Examiner Under the Enablement Requirement</a></li>
                     <li><a href="s2164.html#d0e215797">2164.05-Determination of Enablement Based on Evidence as a Whole</a><ul style="list-style-type: none">
                           <li><a href="s2164.html#d0e215860">2164.05(a)-Specification Must Be Enabling as of the Filing Date</a></li>
                           <li><a href="s2164.html#d0e215949">2164.05(b)-Specification Must Be Enabling to Persons Skilled in the Art</a></li>
                        </ul>
                     </li>
                     <li><a href="s2164.html#d0e215984">2164.06-Quantity of Experimentation</a><ul style="list-style-type: none">
                           <li><a href="s2164.html#d0e216038">2164.06(a)-Examples of Enablement Issues-Missing Information</a></li>
                           <li><a href="s2164.html#d0e216163">2164.06(b)-Examples of Enablement Issues — Chemical Cases</a></li>
                           <li><a href="s2164.html#d0e216273">2164.06(c)-Examples of Enablement Issues – Computer Programming Cases</a></li>
                        </ul>
                     </li>
                     <li><a href="s2164.html#d0e216498">2164.07-Relationship of Enablement Requirement to Utility Requirement of 35 U.S.C. 101</a></li>
                     <li><a href="s2164.html#d0e216700">2164.08-Enablement Commensurate in Scope With the Claims</a><ul style="list-style-type: none">
                           <li><a href="s2164.html#d0e216855">2164.08(a)-Single Means Claim</a></li>
                           <li><a href="s2164.html#d0e216871">2164.08(b)-Inoperative Subject Matter</a></li>
                           <li><a href="s2164.html#d0e216899">2164.08(c)-Critical Feature Not Claimed</a></li>
                        </ul>
                     </li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2165.html">2165-The Best Mode Requirement</a><ul>
                     <li><a href="s2165.html#d0e216999">2165.01-Considerations Relevant to Best Mode</a></li>
                     <li><a href="s2165.html#d0e217148">2165.02-Best Mode Requirement Compared to Enablement Requirement</a></li>
                     <li><a href="s2165.html#d0e217195">2165.03-Requirements for Rejection for Lack of Best Mode</a></li>
                     <li><a href="s2165.html#d0e217264">2165.04-Examples of Evidence of Concealment</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2166-2170.html">2166-2170-[Reserved]</a></li>
               <li xmlns=""><a href="s2171.html">2171-Two Separate Requirements for Claims Under 35 U.S.C. 112 (b) or Pre-AIA 35 U.S.C. 112, Second Paragraph</a></li>
               <li xmlns=""><a href="s2172.html">2172-Subject Matter Which the Inventor or a Joint Inventor Regards as The Invention</a><ul>
                     <li><a href="s2172.html#d0e217526">2172.01-Unclaimed Essential Matter</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2173.html">2173-Claims Must Particularly Point Out and Distinctly Claim the Invention</a><ul>
                     <li><a href="s2173.html#d0e217578">2173.01-Interpreting the Claims</a></li>
                     <li><a href="s2173.html#d0e217598">2173.02-Determining Whether Claim Language is Definite</a></li>
                     <li><a href="s2173.html#d0e217747">2173.03-Correspondence Between Specification and Claims</a></li>
                     <li><a href="s2173.html#d0e217778">2173.04-Breadth Is Not Indefiniteness</a></li>
                     <li><a href="s2173.html#d0e217809">2173.05-Specific Topics Related to Issues Under 35 U.S.C. 112(b) or Pre-AIA 35 U.S.C. 112, Second Paragraph</a><ul style="list-style-type: none">
                           <li><a href="s2173.html#d0e217839">2173.05(a)-New Terminology</a></li>
                           <li><a href="s2173.html#d0e217939">2173.05(b)-Relative Terminology</a></li>
                           <li><a href="s2173.html#d0e218152">2173.05(c)-Numerical Ranges and Amounts Limitations</a></li>
                           <li><a href="s2173.html#d0e218251">2173.05(d)-Exemplary Claim Language (“for example,” “such as”)</a></li>
                           <li><a href="s2173.html#d0e218320">2173.05(e)-Lack of Antecedent Basis</a></li>
                           <li><a href="s2173.html#d0e218380">2173.05(f)-Reference to Limitations in Another Claim</a></li>
                           <li><a href="s2173.html#d0e218409">2173.05(g)-Functional Limitations</a></li>
                           <li><a href="s2173.html#d0e218467">2173.05(h)-Alternative Limitations</a></li>
                           <li><a href="s2173.html#d0e218588">2173.05(i)-Negative Limitations</a></li>
                           <li><a href="s2173.html#d0e218640">2173.05(j)-Old Combination</a></li>
                           <li><a href="s2173.html#d0e218715">2173.05(k)-Aggregation</a></li>
                           <li><a href="s2173.html#">2173.05(l)-[Reserved]</a></li>
                           <li><a href="s2173.html#d0e218748">2173.05(m)-Prolix</a></li>
                           <li><a href="s2173.html#d0e218755">2173.05(n)-Multiplicity</a></li>
                           <li><a href="s2173.html#d0e218827">2173.05(o)-Double Inclusion</a></li>
                           <li><a href="s2173.html#d0e218855">2173.05(p)-Claim Directed to Product-By- Process or Product and Process</a></li>
                           <li><a href="s2173.html#d0e218952">2173.05(q)-“Use” Claims</a></li>
                           <li><a href="s2173.html#d0e219030">2173.05(r)-Omnibus Claim</a></li>
                           <li><a href="s2173.html#d0e219061">2173.05(s)-Reference to Figures or Tables</a></li>
                           <li><a href="s2173.html#d0e219080">2173.05(t)-Chemical Formula</a></li>
                           <li><a href="s2173.html#d0e219126">2173.05(u)-Trademarks or Trade Names in a Claim</a></li>
                           <li><a href="s2173.html#d0e219164">2173.05(v)-Mere Function of Machine</a></li>
                        </ul>
                     </li>
                     <li><a href="s2173.html#d0e219183">2173.06-Practice Compact Prosecution</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2174.html">2174-Relationship Between the Requirements of 35 U.S.C. 112(a) and (b) or Pre-AIA 35 U.S.C. 112, First and Second Paragraphs</a></li>
               <li xmlns=""><a href="s2175-2180.html">2175-2180-[Reserved]</a></li>
               <li xmlns=""><a href="s2181.html">2181-Identifying and Interpreting a 35 U.S.C. 112(f) or Pre-AIA 35 U.S.C. 112, Sixth Paragraph Limitation</a></li>
               <li xmlns=""><a href="s2182.html">2182-Search and Identification of the Prior Art</a></li>
               <li xmlns=""><a href="s2183.html">2183-Making a Prima Facie Case of Equivalence</a></li>
               <li xmlns=""><a href="s2184.html">2184-Determining Whether an Applicant Has Met the Burden of Proving Nonequivalence After a Prima Facie Case Is Made</a></li>
               <li xmlns=""><a href="s2185.html">2185-Related Issues Under 35 U.S.C. 112(a) or (b) and Pre-AIA 35 U.S.C. 112, First or Second Paragraphs</a></li>
               <li xmlns=""><a href="s2186.html">2186-Relationship to the Doctrine of Equivalents</a></li>
               <li xmlns=""><a href="s2187-2189.html">2187-2189-[Reserved]</a></li>
               <li xmlns=""><a href="s2190.html">2190-Prosecution Laches</a></li>
            </ul>  </div>
         </div>
      </div>  </div>
      

  <div style="text-align:right"> Last Modified: 

     

    03/27/2014 10:10:33 

  </div>

</div>

</div>




<!-- End of footer2.html -->


   </body>
</html>